Oculus Innovative Sciences

(OCLS)

, a maker of disinfectants for wounds

that likes to call itself a biopharma firm, continues to lose more money than it brings in in revenue.

The company, which went public in January 2007, released its fiscal fourth-quarter results Thursday after the bell. It lost about $2.2 million on revenue of $1.5 million. It was no Wall Street analysts' coverage. Last year, Oculus lost $4.5 million on revenue of $736,000.

Oculus also issued a batch of financial projections. For its next quarter, which ends in three weeks on June 30, the company said its revenue will come in at $1.8 million. By the end of the year, it hopes to be "cash break even."

Oculus also made a prediction for fiscal 2013. The crystal ball says: revenue of $45 million to $60 million.

Oculus believes that kind of growth will come from re-purposing its disinfectant -- a bleach-and-saline product called Microcyn that it currently sells over the counter -- for treatments other than wounds, including diabetic foot ulcers. Last week, the company said the FDA approved the drug for that use, in addition to several others. Last month, the company announced FDA approval for a gel version of Microcyn. The stock promptly blew higher by a factor of four.

It was moving in the opposite direction in aftermarket action Thursday: down 23 cents to $4.56 from its close in the regular session.

Copyright 2009 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.